Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dikla Czaczkes Akselbrad
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 72
- Beta
- 1.42
- Country
- IL
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -29.76
Financials
Net Income
$-7.85MEBITDA
$-7.48MFree Cash Flow
$0.00EPS (diluted)
$-0.35Shares Outstanding (diluted)
22.64M+2489.7%Operating Expenses
$7.85MCash & Debt
$6.56MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-34.17M | $-2.09 |
| 2024 | $0.00 | $-29.02M | $-4.91 |
| 2023 | $0.00 | $-23.86M | $-16.99 |
| 2022 | $0.00 | $-39.52M | $-61.20 |
| 2021 | $0.00 | $-40.71M | $-67.80 |
| 2020 | $0.00 | $-35.32M | $-4.48 |
| 2019 | $0.00 | $-6.91M | $-15.03 |
| 2018 | $0.00 | $5.92M | $26.70 |
| 2017 | $0.00 | $-54.49M | $-370.58 |
| 2016 | $0.00 | $-11.39M | $-77.48 |
| 2015 | $0.00 | $-8.22M | $-37.62 |
| 2013 | $0.00 | $-3.88M | $-39.58 |
| 2012 | $0.00 | $-1.79M | $-8.08 |
Valuation
PYPDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-51.16%Social Signal Score
Mentions (7)
- Newsmarketbeat.com·1d ago·Positive
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀ PolyPid Submitted Marketing Authorization Application to European Medicines Agency for D-PLEX₁₀₀ Last month
View source ↗ - Newsglobenewswire.com·5d ago·Positive
…ommercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities PETACH TIKVA, Israel, Oct. 01, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that PolyPid and ADVANZ PHARMA have mutually agreed to terminate their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX…
View source ↗ - Newsglobenewswire.com·21d ago·Neutral
PolyPid Announces Participation in Upcoming Fall Investor Conferences PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:
View source ↗ - Newsseekingalpha.com·54d ago·Positive
PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·54d ago·Negative
PolyPid Q2 Earnings Call Highlights PolyPid NASDAQ: PYPD said its second-quarter 2026 was marked by the FDA's acceptance of its new drug application for D-PLEX100 and a commercialization agreement with Azurity Pharmaceuticals covering the United States and Canada.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $0.25 per share
Typical surprise +7.3% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.35 vs $-0.38beat
- Wed, May 13$-0.35 vs $-0.47beat
- Wed, Feb 11$-0.41 vs $-0.34miss
- Wed, Nov 12$-0.37 vs $-0.54beat
- Wed, Aug 13$-0.78 vs $-0.53miss
- Wed, May 14$-0.70 vs $-0.80beat
Estimates and results for PYPD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PYPD officers and directors.
No open-market trades in the recent filings. All 55 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
55 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PYPD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.